|

TNG260 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Tango Therapeutics, Inc.1

Indications

  • Solid Tumors, Adult1
  • Lung Adenocarcinoma1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1
  • Cancer1

Santa Monica, California1 trial

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

UCLA Hematology/Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.